Bausch Health Companies (NYSE:BHC) issued its earnings results on Wednesday. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.21, Morningstar.com reports. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The firm had revenue of $2.12 billion during the quarter, compared to the consensus estimate of $2.08 billion. During the same quarter in the prior year, the firm earned $0.98 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. Bausch Health Companies updated its FY 2019 guidance to EPS.
Bausch Health Companies stock opened at $25.19 on Wednesday. The company has a market capitalization of $8.90 billion, a PE ratio of 6.58, a P/E/G ratio of 0.33 and a beta of 0.63. Bausch Health Companies has a twelve month low of $14.44 and a twelve month high of $28.45. The company has a quick ratio of 0.91, a current ratio of 1.14 and a debt-to-equity ratio of 7.55.
Several equities research analysts have commented on BHC shares. UBS Group raised shares of Bausch Health Companies to a “buy” rating in a research note on Wednesday, January 2nd. Piper Jaffray Companies raised shares of Bausch Health Companies from a “neutral” rating to an “overweight” rating and set a $27.00 target price for the company in a research note on Tuesday, January 1st. Morgan Stanley raised shares of Bausch Health Companies from an “equal weight” rating to an “overweight” rating and set a $32.00 target price for the company in a research note on Monday, November 5th. Mizuho reaffirmed a “buy” rating and issued a $39.00 target price on shares of Bausch Health Companies in a research note on Sunday, January 6th. Finally, HC Wainwright raised shares of Bausch Health Companies from an “average” rating to a “buy” rating in a research note on Friday, December 14th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company’s stock. Bausch Health Companies has an average rating of “Hold” and a consensus target price of $27.61.
In related news, insider Thomas Appio purchased 25,440 shares of Bausch Health Companies stock in a transaction dated Friday, December 14th. The stock was bought at an average price of $22.96 per share, for a total transaction of $584,102.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.54% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in BHC. APG Asset Management N.V. boosted its holdings in Bausch Health Companies by 59.3% during the fourth quarter. APG Asset Management N.V. now owns 139,354 shares of the company’s stock worth $2,253,000 after purchasing an additional 51,900 shares during the last quarter. HRT Financial LLC boosted its holdings in Bausch Health Companies by 20.6% during the fourth quarter. HRT Financial LLC now owns 25,133 shares of the company’s stock worth $464,000 after purchasing an additional 4,288 shares during the last quarter. grace capital boosted its holdings in Bausch Health Companies by 2.0% during the fourth quarter. grace capital now owns 30,837 shares of the company’s stock worth $570,000 after purchasing an additional 600 shares during the last quarter. Macquarie Group Ltd. acquired a new position in Bausch Health Companies during the fourth quarter worth $418,000. Finally, First Allied Advisory Services Inc. boosted its holdings in Bausch Health Companies by 29.3% during the fourth quarter. First Allied Advisory Services Inc. now owns 17,843 shares of the company’s stock worth $327,000 after purchasing an additional 4,042 shares during the last quarter. Institutional investors own 50.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Bausch Health Companies (BHC) Announces Quarterly Earnings Results” was first reported by Zolmax and is owned by of Zolmax. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://zolmax.com/investing/bausch-health-companies-bhc-announces-quarterly-earnings-results/2913872.html.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
See Also: What is net income?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.